Chrissy Metz Discusses Her Health Choices and Use of GLP-1 Medication

Chrissy Metz, known for her role in “This Is Us,” has openly shared her decision to use a GLP-1 medication. At 45, Metz had initial reservations. Speaking with TODAY, she emphasized, “I’m not a girl who wants to follow trends because some friends do it.”

Her perspective changed after a friend explained the health benefits of these medications. Having seen her father suffer from obesity-related issues, Metz thought, “Oh, maybe I can get ahead of it.” With her doctors’ approval, she decided to proceed.

Metz has now partnered with the healthcare company Ro, which supplies GLP-1 medications via telehealth. These drugs mimic a hormone the body releases post-eating, helping to reduce cravings and promote a feeling of fullness.

“If nothing changes, nothing changes,” she reflected on her decision.

Having tried various diets and group therapy since age 9 without lasting success, Metz welcomed the change. According to her, the GLP-1 drug has alleviated her constant thoughts about food, a significant shift she finds “unbelievable.”

Initially skeptical about such improvements, she has started to experience creativity and mental space freed from “food noise.” The shift is more than medication; it’s a lifestyle change. Metz clarifies, “It’s not the easy way out. It requires diligence.”

Prioritizing herself, a notion she had long aspired to, is now a practice. Working on Broadway’s “& Juliet” as Angélique, she has noticed increased stamina across eight shows weekly. Changes in her menstrual cycle, inflammation reduction, and improved joint comfort reflect these health benefits. Costume adjustments are necessary due to her changing measurements.

Weight numbers don’t concern Metz; she avoids focusing on scales. “It’s overwhelming and leads to a new obsession,” she explains. Emphasizing long-term benefits, she broadens her choices in food, music, and television.

Strength is also a focus. Besides the walking and dancing required on stage, Metz began strength training a year ago, preparing for perimenopause. The World Health Organization supports strength training for GLP-1 users.

Metz advises thorough consideration before starting GLP-1 drugs. Research and skepticism are essential, as is consulting a doctor or trusted health professional.

“Nothing is for everybody, and skepticism is important with what we consume,” she advises.

Understanding potential public scrutiny, Metz remains undeterred. “People talk, but they aren’t in my body or life daily. They haven’t faced my trauma,” she says, encouraging personal health choices.